ArticleSaudi journal of biological sciences2021
Overexpression of
Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Schisandrin B exerts anti-colorectal cancer effect through CXCL2/ERK/DUSP11 signaling pathway.Cancer cell international · 2025Article
- IncreasedPharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Article
- Expression of CXCL8 (IL-8) in the Pathogenesis of T-Cell Acute Lymphoblastic Leukemia Patients.Cureus · 2023Article
- Higher Expression Levels ofMedicina (Kaunas, Lithuania) · 2023Article
- Epigallocatechin-3-gallate inhibits the formation of neutrophil extracellular traps and suppresses the migration and invasion of colon cancer cells by regulating STAT3/CXCL8 pathway.Molecular and cellular biochemistry · 2023Article
- CXCL8 and the peritoneal metastasis of ovarian and gastric cancer.Frontiers in immunology · 2023Review
- The Expression Patterns of Human Cancer-Testis Genes Are Induced through Epigenetic Drugs in Colon Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Expression Profile of MAGE-B1 Gene and Its Hypomethylation Activation in Colon Cancer.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the leading causes of death in Saudi Arabia. CRC mostly affects older age groups, but now a days it also appears frequently at a young age. However, the complete genetic etiology of CRC remains unknown. To identify the genetic factors responsible for this cancer type and to search for biomarkers for early diagnosis and prevention, we collected sixteen CRC tumor tissue samples and six normal colon tissues and extracted mRNA and synthesized cDNA. We then performed microarray transcriptomic profiling of Saudi patients with colon cancer. Gene expression was analyzed using Partek Genomics Suite, and principal component analysis (PCA) was performed to separate the different clusters of colon cancer and healthy tissues. Distinct differences in gene expression profiles were observed between colon cancer and normal tissue samples. Subsequently, we validated gene expression using real-time PCR. We found that the C-X-C motif chemokine ligand 8 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.